Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mRNA-3283
- Development stage
- Unknown
- Lead developer
- Moderna
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
mRNA-3283 is an investigational messenger RNA (mRNA) vaccine candidate developed by Moderna, specifically designed to provide protection against Influenza B viruses. The vaccine encodes the hemagglutinin (HA) glycoproteins from both the Victoria and Yamagata lineages of Influenza B, which are the two primary lineages circulating globally. Utilizing Moderna's proprietary lipid nanoparticle (LNP) delivery technology, the vaccine instructs host cells to synthesize these viral antigens, thereby eliciting a robust immune response characterized by the production of neutralizing antibodies and T-cell activation. mRNA-3283 is intended to serve as a standalone component or to optimize the B-strain coverage in Moderna's broader seasonal influenza vaccine portfolio, addressing the specific evolutionary dynamics and manufacturing challenges associated with Influenza B.
- Other names
- Influenza B vaccineBivalent Influenza B mRNA vaccine
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on mRNA-3283.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mRNA-3283.